<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064999</url>
  </required_header>
  <id_info>
    <org_study_id>FDRT-002</org_study_id>
    <nct_id>NCT01064999</nct_id>
  </id_info>
  <brief_title>A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer</brief_title>
  <official_title>An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for local advanced rectal
      cancer. Pathological complete response (pCR) is an important prognostic factor for local
      control and survival. A high intensity CRT increases not only the pCR rate, but also
      toxicity, especially diarrhea. Compared with traditional RT technique, intensity-modified
      radiation therapy (IMRT) can decrease the toxicity of diarrhea because of low volume of high
      dose for small bowel. Therefore, IMRT technique provides an opportunity to improve the dose
      intensity of neoadjuvant CRT. The investigators hypothesize that a higher treatment dose
      induces a high rate of pCR and design a two-arm trial. in this trial, low intensity CRT
      includes the whole pelvic irradiation of 50Gy together with Oxaliplatin and Capecitabine
      weekly. While in high intensity group, additional concomitant 5Gy for primary tumor and a
      cycle of Xelox are prescribed. All patients will receive a total mesorectal excision (TME) 8
      weeks after CRT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of pathological complete response (pCR)</measure>
    <time_frame>within 14days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>every week during radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local recurrence</measure>
    <time_frame>every half year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>every half year after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every half year after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>High intensity group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(RT 55Gy + CapOx) + a cycle of Xelox + Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low instensity group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(RT 50Gy + CapOx) + Surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day</description>
    <arm_group_label>High intensity group</arm_group_label>
    <arm_group_label>Low instensity group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks</description>
    <arm_group_label>High intensity group</arm_group_label>
    <arm_group_label>Low instensity group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>High intensity group:55Gy Low intensity group:50Gy</description>
    <arm_group_label>High intensity group</arm_group_label>
    <arm_group_label>Low instensity group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Lower anterior resection or abdominoperineal resection</description>
    <arm_group_label>High intensity group</arm_group_label>
    <arm_group_label>Low instensity group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with rectal adenocarcinoma

          -  Clinical staged T3/4 or any node-positive disease

          -  Age: 18-75 years

          -  Karnofsky Performance Status &gt; 80

          -  Adequate bone marrow reserve, renal and hepatic functions

          -  Without previous antitumoural chemotherapy

          -  No evidence of metastatic disease

          -  Written informed consent before randomization

        Exclusion Criteria:

          -  Previous pelvis radiotherapy.

          -  Previous antitumoural chemotherapy

          -  Clinically significant internal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Zhu, MD</last_name>
    <email>leo.zhu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhen Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhen Zhang</investigator_full_name>
    <investigator_title>Division Head, Division of Radiation Oncology,Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>intensity-modulated radiation therapy</keyword>
  <keyword>pathological complete response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

